Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats

BACKGROUND: Remdesivir was the first prodrug approved to treat coronavirus disease 2019 (COVID-19) and has the potential to be used during pregnancy. However, it is not known whether remdesivir and its main metabolite, GS-441524 have the potential to cross the blood-placental barrier. We hypothesize...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ling, Lin, I-Hsin, Lin, Lie-Chwen, Dalley, Jeffrey W., Tsai, Tung-Hu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166662/
https://www.ncbi.nlm.nih.gov/pubmed/35671622
http://dx.doi.org/10.1016/j.ebiom.2022.104095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166662/
https://www.ncbi.nlm.nih.gov/pubmed/35671622
http://dx.doi.org/10.1016/j.ebiom.2022.104095

Ejemplares similares